Evidence map›Paper›PMID 25939870›Full record

ArticleBMC cancer2015

ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly.

Tommaso Selmi, Claudia Alecci, Miriam dell' Aquila, Lucia Montorsi, Andrea Martello, Filippo Guizzetti, Nicola Volpi, Sandra Parenti, Sergio Ferrari, Paolo Salomoni and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Microorganisms · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Promoter Methylation Leads to DecreasedFrontiers in medicine · 2020
    Article
  8. Article
  9. Article
  10. The role of RNA-binding protein tristetraprolin in cancer and immunity.Medical oncology (Northwood, London, England) · 2017
    Review
  11. Cell cycle RNA regulons coordinating early lymphocyte development.Wiley interdisciplinary reviews. RNA · 2017
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Tommaso SelmiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. tselmi@gmail.com.
Claudia AlecciDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. claudia.alecci@gmail.com.
Miriam dell' AquilaDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. miriam.dellaquila@gmail.com.
Lucia MontorsiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. lucia.montorsi@unimore.it.
Andrea MartelloDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. martelloandrea@gmail.com.
Filippo GuizzettiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. 72295@studenti.unimore.it.
Nicola VolpiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. nicola.volpi@unimore.it.
Sandra ParentiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. sandra.parenti@unimore.it.
Sergio FerrariDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. sergio.ferrari@unimore.it.
Paolo SalomoniSamantha Dickson Brain Cancer Unit, UCL Cancer Institute, London WC1E 6BT, United Kingdom. p.salomoni@ucl.ac.uk.
Alexis GrandeDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. alexis.grande@unimore.it.
Tommaso Zanocco-MaraniDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, 41125, Italy. zanocco@unimore.it.
University of Modena and Reggio Emilia · ITUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundZFP36 is an mRNA binding protein that exerts anti-tumor activity in glioblastoma by triggering cell death, associated to an increase in the stability of the kinase RIP1.

methodsWe used cell death assays, size exclusion chromatography, Co-Immunoprecipitation, shRNA lentivectors and glioma neural stem cells to determine the effects of ZFP36 on the assembly of a death complex containing RIP1 and on the induction of necroptosis.

resultsHere we demonstrate that ZFP36 promotes the assembly of the death complex called Ripoptosome and induces RIP1-dependent death. This involves the depletion of the ubiquitine ligases cIAP2 and XIAP and leads to the association of RIP1 to caspase-8 and FADD. Moreover, we show that ZFP36 controls RIP1 levels in glioma neural stem cell lines.

conclusionsWe provide a molecular mechanism for the tumor suppressor role of ZFP36, and the first evidence for Ripoptosome assembly following ZFP36 expression. These findings suggest that ZFP36 plays an important role in RIP1-dependent cell death in conditions where IAPs are depleted.

Indexed as

ApoptosisBaculoviral IAP Repeat-Containing 3 ProteinCell Line, TumorEnzyme StabilityGliomaHEK293 CellsHumansInhibitor of Apoptosis ProteinsNeoplastic Stem CellsProtein MultimerizationProteolysisReceptor-Interacting Protein Serine-Threonine KinasesTristetraprolinUbiquitin-Protein LigasesX-Linked Inhibitor of Apoptosis ProteinBaculoviral IAP Repeat-Containing 3 ProteinBIRC3 protein, humanInhibitor of Apoptosis ProteinsReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanTristetraprolinUbiquitin-Protein LigasesXIAP protein, humanX-Linked Inhibitor of Apoptosis ProteinZFP36 protein, human

Identifiers

PMID25939870
PMCPMC4424499
OpenAlexW1518843985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.